Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4857754
Max Phase: Preclinical
Molecular Formula: C47H66N3O12P
Molecular Weight: 896.03
Molecule Type: Unknown
Associated Items:
ID: ALA4857754
Max Phase: Preclinical
Molecular Formula: C47H66N3O12P
Molecular Weight: 896.03
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCOP(=O)(/C=C/C(NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1C[C@@H](O[C@H]2O[C@@H]3O[C@@]4(C)CC[C@H]5[C@H](C)CC[C@@H]([C@H]2C)[C@@]35OO4)CN1C(=O)OCc1ccccc1)c1ccccc1)OCC
Standard InChI: InChI=1S/C47H66N3O12P/c1-8-56-63(54,57-9-2)25-23-38(34-18-14-11-15-19-34)48-41(51)39(26-30(3)4)49-42(52)40-27-35(28-50(40)45(53)55-29-33-16-12-10-13-17-33)58-43-32(6)37-21-20-31(5)36-22-24-46(7)60-44(59-43)47(36,37)62-61-46/h10-19,23,25,30-32,35-40,43-44H,8-9,20-22,24,26-29H2,1-7H3,(H,48,51)(H,49,52)/b25-23+/t31-,32-,35-,36+,37+,38?,39+,40+,43+,44-,46-,47-/m1/s1
Standard InChI Key: SOIXVDMTFRVKPR-CQKDAFNJSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 896.03 | Molecular Weight (Monoisotopic): 895.4384 | AlogP: 8.16 | #Rotatable Bonds: 17 |
Polar Surface Area: 169.42 | Molecular Species: NEUTRAL | HBA: 12 | HBD: 2 |
#RO5 Violations: 3 | HBA (Lipinski): 15 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 12.14 | CX Basic pKa: | CX LogP: 7.34 | CX LogD: 7.34 |
Aromatic Rings: 2 | Heavy Atoms: 63 | QED Weighted: 0.12 | Np Likeness Score: 1.15 |
1. Aratikatla EK, Kalamuddin M, Rana KC, Datta G, Asad M, Sundararaman S, Malhotra P, Mohmmed A, Bhattacharya AK.. (2021) Combating multi-drug resistant malaria parasite by inhibiting falcipain-2 and heme-polymerization: Artemisinin-peptidyl vinyl phosphonate hybrid molecules as new antimalarials., 220 [PMID:33901900] [10.1016/j.ejmech.2021.113454] |
Source(1):